Design, Synthesis, and Pharmacological Evaluation of Isoindoline Analogues as New HPK1 Inhibitors
Journal of Medicinal Chemistry · 14.12.2023 · 66 (23) · 16201-16221
DOI: 10.1021/acs.jmedchem.3c01571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 22.11.2023. Verfasst von Chenghu Xie und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shang…. Hauptthemen laut MEDLINE: Signal Transduction, T-Lymphocytes. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China, Shanghai-Zhangjiang National Independent Innovation of China.
Abstract (Originalsprache)
Hematopoietic progenitor kinase 1 (HPK1) is an important negative regulator in T-cell receptor signaling and as a promising key target for immunotherapy. Herein, based on the reported HPK1 inhibitor 2 featuring an isofuranone component, a structural optimization approach was conducted leading to several series of derivatives characterized by containing an isoindoline structural motif. Compound 49 was identified as a new potent HPK1 inhibitor with an IC50 value of 0.9 nM, more potent than compound 2 (5.5 nM). It also has an improved IV profile in rats and enhanced aqueous solubility. It effectively inhibited pSLP76 and reinvigorated T-cell receptor (TCR) signaling, promoting T-cell function and cytokine production both in naïve and antigen-specific T cells. Furthermore, compound 49 reversed the inhibition on T-cell activity mediated by classic immunosuppressive factors in the tumor microenvironment (TME). In the murine CT-26 tumor model, this compound reinvigorated the T cell and synergistically enhanced the antitumor efficacy of anti-PD1 at a well-tolerant dosage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
- National Key Laboratory of Innovative Immunotherapy, Shanghai Jiao Tong University, 800 Dongchuan Road, Minhang District, Shanghai 200240, China.
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou 310053, China.
- Lingang Laboratory, Shanghai 200210, China.
ORCID-Profile: Chunyong Ding, Ao Zhang
Förderung
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China
- Shanghai-Zhangjiang National Independent Innovation of China
- Innovative research team of high-level local universities in Shanghai
Zitieren
APA
Xie, C., Liu, B., Song, Z., Yang, Y., Dai, M., Gao, Y., Yao, Y., Ding, C., Ai, J., & Zhang, A. (2023). Design, Synthesis, and Pharmacological Evaluation of Isoindoline Analogues as New HPK1 Inhibitors. Journal of Medicinal Chemistry, 66(23), 16201-16221. https://doi.org/10.1021/acs.jmedchem.3c01571
Vancouver
Xie C, Liu B, Song Z, Yang Y, Dai M, Gao Y, et al. Design, Synthesis, and Pharmacological Evaluation of Isoindoline Analogues as New HPK1 Inhibitors. Journal of Medicinal Chemistry. 2023;66(23):16201-16221. doi:10.1021/acs.jmedchem.3c01571
BibTeX
@article{Xie2023,
author = {Xie, Chenghu and Liu, Bo and Song, Zilan and Yang, Ye and Dai, Mengdi and Gao, Yinglei and Yao, Yujia and Ding, Chunyong and Ai, Jing and Zhang, Ao},
title = {Design, Synthesis, and Pharmacological Evaluation of Isoindoline Analogues as New HPK1 Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {23},
pages = {16201--16221},
doi = {10.1021/acs.jmedchem.3c01571}
}
EUVIMED